

"Express Mail" mailing label number EL018107437US

Date of Deposit November 30, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202-0327.

Olga M. Franz  
Printed Name

Olga M. Franz  
Signature

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Hermeling, Ronald N., et al. )  
 )  
For : GLUCAGON-LIKE PEPTIDE-1 )  
CRYSTALS )  
 )  
Docket No. : X-10242A )

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D. C. 20231  
Sir:

This preliminary amendment accompanies a continuation application of allowed application no. 09/209,799.

Please make the following amendments:

**In the Specification**

Add the following section immediately prior to the heading "Field of Invention":

**Cross Reference to Related Application**

This application claims the benefit of U.S. Provisional Application Serial Number 60/069,728, filed December 16, 1997 and U.S. Nonprovisional Application Serial Number 09/209,799, filed December 11, 1998.

In the Claims

Please cancel all claims and add the following new claims.

80. Crystals comprising zinc, and a GLP-1 analog wherein the crystals have a tetragonal flat rod shaped or plate-like morphology and the GLP-1 analog is a peptide of the formula:

$R_1$ -X-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Y-Gly-Gln-Ala-Ala-Lys-Z-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg- $R_2$

wherein:  $R_1$  is selected from the group consisting of L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, beta-hydroxy-histidine, homohistidine, alpha-fluoromethyl-histidine, and alpha-methyl-histidine; X is selected from the group consisting of Ala, Gly, Val, Thr, Met, Ile, and alpha-methyl-Ala; Y is selected from the group consisting of Glu, Gln, Ala, Thr, Ser, and Gly; Z is selected from the group consisting of Glu, Gln, Ala, Thr, ser, and Gly; and  $R_2$  is selected from the group consisting of  $NH_2$ , and Gly-OH.


81. The crystals of Claim 80 wherein X is selected from the group consisting of Gly, Val, Thr, Met, Ile, and alpha-methyl-Ala.
82. The crystals of Claim 81 having a size from between about 2-25 microns by 10-150 microns with a depth from about 0.5-5 microns.
83. A pharmaceutical formulation comprising crystals as claimed in Claim 80 together with one or more pharmaceutically acceptable diluents, carriers, or excipients.

84. A pharmaceutical formulation comprising crystals as claimed in Claim 81 with one or more pharmaceutically acceptable diluents, carriers, or excipients.
85. A pharmaceutical formulation comprising crystals as claimed in Claim 82 with one or more pharmaceutically acceptable diluents, carriers, or excipients.

Remarks

Support for these claims can be found in the originally filed claims and throughout the Specification. For example, tetragonal flat rod shaped or plate-like morphology is discussed on p. 3, line 18-30, p. 4, line 15-22, p. 10; the GLP-1 analog genus formula is discussed on the bottom of p. 5 and top of p. 6; position 8 analogs are discussed on p. 11, line 8-12; the size range of the crystals as specified in claim 82 is discussed on p. 10, line 3-6; and pharmaceutical formulations are discussed on p. 13-15.

Respectfully submitted,



Mark J. Stewart, Ph.D.  
Attorney for Applicants  
Registration No. 43,936  
Phone: 317-276-0280

Eli Lilly and Company  
Patent Division/MJS  
Lilly Corporate Center  
Indianapolis, Indiana 46285

November 29, 2001